vTv Therapeutics (NASDAQ:VTVT) Shares Cross Above 50 Day Moving Average – Time to Sell?

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $36.23 and traded as high as $37.99. vTv Therapeutics shares last traded at $35.31, with a volume of 16,208 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on VTVT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Roth Mkm started coverage on vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $49.00 target price (up from $40.00) on shares of vTv Therapeutics in a research note on Tuesday, January 27th. Wall Street Zen upgraded vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price objective (up previously from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.25.

vTv Therapeutics Price Performance

The stock has a 50-day simple moving average of $36.22 and a 200 day simple moving average of $27.20. The company has a market capitalization of $135.07 million, a PE ratio of -10.33 and a beta of 0.50.

Hedge Funds Weigh In On vTv Therapeutics

Several hedge funds have recently added to or reduced their stakes in VTVT. Baker BROS. Advisors LP raised its position in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after acquiring an additional 51,000 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics during the 4th quarter worth approximately $731,000. Finally, Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics in the 4th quarter valued at approximately $221,000. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.